HKU Scholars Hub: Browsing DSpace

Browsing by Author Nixon, AB

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 10 to 21 of 21 < previous

	Title	Author(s)	Issue Date	Views
	Modulation of angiogenic biomarkers in patients receiving high-dose TRC105 Proceeding/Conference:Journal of Clinical Oncology	Liu, Y Starr, M Brady, JC Pang, HMH Dellinger, A Leigh, BR Theuer, CP Hurwitz, H Nixon, AB	2012	49
	Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors Proceeding/Conference:Journal of Clinical Oncology	Liu, Y Starr, M Pang, HMH Marcello, J Leigh, BR Theuer, CP Hurwitz, H Nixon, AB	2011	67
	Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer Journal:Cancer Medicine	Liu, Y Starr, MD Brady, JC Dellinger, A Pang, HMH Adams, B Theuer, CP Lee, NY Hurwitz, HI Nixon, AB	7-Mar-2014	68
	Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105 Journal:Molecular Cancer Therapeutics	Liu, Y Starr, MD Brady, JC Rushing, C Pang, H Adams, B Alvarez, D Theuer, CP Hurwitz, HI Nixon, AB	2018	15
	Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors Proceeding/Conference:Journal of Clinical Oncology	Jia, J Li, H Dellinger, A Pang, HMH Russell, KB Hurwitz, H Nixon, AB	2012	49
	A phase I study of ABT-510 plus bevacizumab in advanced solid tumors Journal:Cancer Medicine	Uronis, HE Cushman, SM Bendell, JC Blobe, GC Morse, MA Nixon, AB Dellinger, A Starr, MD Li, H Meadows, K Gockerman, J Pang, HMH Hurwitz, HI	2013	84
	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors Journal:Invest New Drugs	Rangwala, F Bendell, JC Kozloff, MF Arrowood, CC Dellinger, A Meadows, J Tourt-Uhlig, S Murphy, J Meadows, KL Starr, A Broderick, S Brady, JC Cushman, SM Morse, MA Uronis, HE Hsu, SD Zafar, SY Wallace, J Starodub, AN Strickler, JH Pang, HMH Nixon, AB Hurwitz, HI	2014	59
	Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer Journal:Investigational New Drugs	Strickler, JH McCall, S Nixon, AB Brady, JC Pang, H Rushing, C Cohn, A Starodub, A Arrowood, C Haley, S Meadows, KL Morse, MA Uronis, HE Blobe, GC Hsu, SD Zafar, SY Hurwitz, HI	2014	61
	A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors Journal:Cancer Chemotherapy and Pharmacology	Uronis, HE Jia, J Bendell, J Howard, L Ready, NA Lee, PA Starr, MD Dellinger, A Pang, HMH Nixon, AB	2015
	Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303 Proceeding/Conference:Journal of Clinical Oncology	Nixon, AB Pang, HMH Starr, M Hollis, D Friedman, PN Bertagnolli, MM Kindler, HL Goldberg, RM Venook, AP Hurwitz, H	2011	51
	Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance) Journal:Clinical Cancer Research	Nixon, AB Nixon, AB Nixon, AB Pang, HMH Starr, MD Friedman, PN Bertagnolli, MM Kindler, HL Goldberg, RM Venook, AP Hurwitz, HI	2013
	Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance) Proceeding/Conference:Journal of Clinical Oncology	Hatch, AJ Pang, HMH Starr, MD Brady, JC Jia, J Chen, J Sibley, A Owzar, K Niedzwiecki, D Venook, AP Cushman, SM Hurwitz, H Nixon, AB	2014

Showing results 10 to 21 of 21 < previous